| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Epizyme Inc (F: EPE)
EPE Technical Analysis
5
| As on 16th Jan 2023 EPE STOCK Price closed @ 555.00 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 3.60 & Strong Buy for SHORT-TERM with Stoploss of 6.46 we also expect STOCK to react on Following IMPORTANT LEVELS. |
EPESTOCK Price
| Open | 560.00 | Change | Price | % |
| High | 560.00 | 1 Day | 14.00 | 2.59 |
| Low | 540.00 | 1 Week | 15.00 | 2.78 |
| Close | 555.00 | 1 Month | 4.00 | 0.73 |
| Volume | 40379 | 1 Year | 548.33 | 8220.84 |
| 52 Week High 570.00 | 52 Week Low 0.36 | ||||
F Germany Most Active Stocks
| ENB | 47.60 | -0.92% |
| TEF | 3.84 | -0.52% |
| TEF | 3.84 | -0.52% |
| WHL | 5150.00 | -0.44% |
| WDI | 0.05 | -37.50% |
| WDI | 0.05 | -37.50% |
| WDI | 0.05 | -37.50% |
| WDI | 0.05 | -37.50% |
| WDI | 0.05 | -37.50% |
| TOE | 0.02 | 0.00% |
F Germany Top Gainers Stocks
F Germany Top Losers Stocks
| EPE Daily Charts |
EPE Intraday Charts |
Whats New @ Bazaartrend |
EPE Free Analysis |
|
|
EPE Important Levels Intraday
| RESISTANCE | 593.54 |
| RESISTANCE | 581.18 |
| RESISTANCE | 573.54 |
| RESISTANCE | 565.90 |
| SUPPORT | 544.10 |
| SUPPORT | 536.46 |
| SUPPORT | 528.82 |
| SUPPORT | 516.46 |
EPE Forecast May 2024
| 4th UP Forecast | 559.41 |
| 3rd UP Forecast | 558 |
| 2nd UP Forecast | 557.12 |
| 1st UP Forecast | 556.25 |
| 1st DOWN Forecast | 553.75 |
| 2nd DOWN Forecast | 552.88 |
| 3rd DOWN Forecast | 552 |
| 4th DOWN Forecast | 550.59 |
EPE Weekly Forecast
| 4th UP Forecast | 555.92 |
| 3rd UP Forecast | 555.63 |
| 2nd UP Forecast | 555.44 |
| 1st UP Forecast | 555.26 |
| 1st DOWN Forecast | 554.74 |
| 2nd DOWN Forecast | 554.56 |
| 3rd DOWN Forecast | 554.37 |
| 4th DOWN Forecast | 554.08 |
EPE Forecast2024
| 4th UP Forecast | 1710.53 |
| 3rd UP Forecast | 1339.94 |
| 2nd UP Forecast | 1110.88 |
| 1st UP Forecast | 881.81 |
| 1st DOWN Forecast | 228.19 |
| 2nd DOWN Forecast | -0.88 |
| 3rd DOWN Forecast | -229.94 |
| 4th DOWN Forecast | -600.53 |
Epizyme Inc ( F Germany Symbol : EPE )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
EPE Business Profile
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops Tazemetostat in combination with rituximab in patients with follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with platinum-resistant solid tumors, such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. In addition, it develops Tazemetostat in patients with castration-resistant prostate cancer; and adults and pediatrics with INI1-negative tumors. Further, the company develops pinometostat for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. Epizyme, Inc. has collaboration agreements with Genentech Inc.; Glaxo Group Limited; Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; and HUTCHMED (China) Limited. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Address: 400 Technology Square, Cambridge, MA, United States, 02139
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service